Coherus Biosciences | CHRS - Ebitda


Coherus Biosciences reported $-43.33M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
Baxter International USD 309M 756M Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Fujifilm JPY 149.91B 17.19B Mar/2026
Gilead Sciences USD 3.02B 1.01B Dec/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Myriad Genetics USD 14.3M 4M Dec/2025
Pacira USD 40.24M 1.53M Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Teva Pharmaceutical Industries USD 474M 581M Jun/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xencor USD -51.05M 55.28M Dec/2025
Zoetis USD 939M 101M Dec/2025